The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 22, 2022

Filed:

Apr. 28, 2019
Applicant:

The Regents of the University of California, Oakland, CA (US);

Inventors:

Davide Ruggero, Emerald Hill, CA (US);

Hao Nguyen, San Francisco, CA (US);

Peter Carroll, San Francisco, CA (US);

Crystal Conn, Oakland, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); A61P 35/02 (2006.01); G01N 33/574 (2006.01); G01N 33/573 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61P 35/02 (2018.01); G01N 33/573 (2013.01); G01N 33/57434 (2013.01); A61K 45/06 (2013.01); G01N 2440/14 (2013.01);
Abstract

In cancers such as prostate cancer, the combination of PTEN loss and activation of Myc activates an adaptive stress response that enables tumor cells to escape the stress of massively upregulated protein synthesis. This pro-survival response is mediated by the PERK-phosphorylated eIF2α axis of the UPR adaptive response. Agents that disrupt PERK-eIF2α pathways disrupt the adaptive response and lead to cancer cell death from uncontrolled growth. For example, ISRIB and derivatives may be employed as therapeutic agents to disrupt PERK-mediated adaptive mechanisms. Additionally PTEN loss and activation of Myc provides a diagnostic marker that enables better prognosis and the selection of amenable treatments.


Find Patent Forward Citations

Loading…